Slow Uptake of HiSeq, Reduced Reagent Use Take Toll on Illumina's Revenues
October 11, 2011
Slow Uptake of HiSeq, Reduced Reagent Use Take Toll on Illumina's Revenues
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - Resurgence in HiSeq Sales Helps Drive Illumina Revenue Growth in Q1 2013
April 23, 2013 / In Sequence - MiSeq, Consumables, Services Drive Illumina's Q4 Revenues as it Begins Work on Nanopore Sequencing
January 29, 2013 / In Sequence - Record Orders for MiSeq, Consumables Drive Illumina's Q1 Sequencing Revenues
April 24, 2012 / In Sequence - Illumina Customers 'Back to Work' as Q4 Sequencing Consumables Recover, MiSeq Drives Growth
February 14, 2012 / In Sequence